Novel CenterCross and MultiCross devices for the treatment of infrainguinal chronic total occlusions: initial single-centre experience.

Journal Article (Journal Article)

AIMS: Our aim was to evaluate the effectiveness and safety of CenterCross/MultiCross devices to facilitate the crossing of chronic total occlusions in peripheral arteries. METHODS AND RESULTS: This was a single-centre study in which 53 consecutive patients who were not amenable to initial attempts at crossing using standard guidewires underwent an attempt to recanalise chronically occluded infrainguinal peripheral arteries with MultiCross/CenterCross devices. The primary endpoint of interest was the ability to advance the guidewire beyond the chronic total occlusion (CTO) lesions with the use of these devices. Safety endpoints were freedom from bleeding, distal embolisation and vessel perforation, dissection or need for emergent surgical intervention. Popliteal artery and below lesions were the most commonly treated, comprising 89% of the total. The CTO lesions were crossed successfully in 92.4% of the cases within a relatively short time (5.5±3.5 minutes). There was no bleeding, dissection or need for emergent surgery and 98.1% and 96.2% of the patients were free from distal embolisation and perforations, respectively. CONCLUSIONS: Our study demonstrated that MultiCross and CenterCross were effective and safe for recanalisation of peripheral CTO lesions which were not amenable to conventional guidewires. Further study is required to define the role of these novel devices in the treatment of complex lesions, particularly CTOs in patients with peripheral arterial disease.

Full Text

Duke Authors

Cited Authors

  • Jalal, S; Lalonde, TA; Yamasaki, H; Boshara, A; Rosman, HS; Mehta, RH; Davis, TP

Published Date

  • January 22, 2016

Published In

Volume / Issue

  • 11 / 9

Start / End Page

  • 1063 - 1069

PubMed ID

  • 26788708

Electronic International Standard Serial Number (EISSN)

  • 1969-6213

Digital Object Identifier (DOI)

  • 10.4244/EIJV11I9A214


  • eng

Conference Location

  • France